在治疗先进的默克尔细胞癌的avelumab: 一个系统的审查

相关实验视频

Updated: Jul 3, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Ajay N Sharma¹, Karishma S Shah¹, Aditi A Sharma¹

¹Department of Dermatology, University of California, Irvine, Irvine, California.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

|February 13, 2024

概括

艾维卢马布治疗为晚期梅克尔细胞癌 (MCC) 提供了持久的反应. 这种编程死亡联体-1 抑制剂在MCC患者中显示出显著的整体反应率和改善的生存率.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

默克尔细胞癌 (MCC) 是一种具有有限治疗选择的侵袭性皮肤癌.
编程死亡联体-1 (PD-L1) 抑制剂Avelumab已成为高级MCC的有希望的治疗方法.

研究的目的:

评估阿维卢马布在治疗晚期MCC的疗效和安全性.
评估与阿维卢马布治疗相关的整体应答率 (ORR),整体存活率 (OS) 和与治疗相关的不良事件.
综合来自研究的证据,以阿维卢马布作为单一疗法或结合治疗先进的MCC.

主要方法:

对48项涉及1565名患有III或IV期MCC的患者的研究进行了系统审查和元分析.
纳入标准侧重于AVELUMAB的使用 (单疗或组合疗法) 对于先进的MCC.
主要结局措施包括ORR,OS和与治疗相关的不良事件.

主要成果:

总体应答率 (ORR) 为46.1% (20.7%的完整应答,25.4%的部分应答),随访时间中位数为9.5个月.
平均整体存活期 (OS) 为23.1个月,其中1年,2年和5年的OS率分别为58%,47%和28%.
最常见的不良事件包括宪法 (44%),胃肠道 (19%) 和皮肤病 (12%) 的症状.

结论:

阿维卢马布单疗法和组合疗法在改善高级MCC的ORR和OS方面表现出有效性.
阿维卢马布对于患有晚期MCC的患者来说是一个有价值的治疗选择.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...